When GLP-1 medications first broke into mainstream culture, Dr. Betty Murray was skeptical. Not because she doubted the biology. She was skeptical of the way women were being rushed into care.
In her Menopause Mastery episode, she describes a system in which a woman could potentially fast-track a prescription through telehealth with little meaningful verification, no real conversation about nutrition or resistance training, and no plan for what happened if the medication made it difficult to eat. Her concern was never that women should simply try harder. It was that midlife women deserved more than a high-dose prescription and a shrug.
Then she changed her mind.
“I’ve changed my mind about something big.”
The claim at the center of this conversation is this: What if the better response to GLP-1s is neither fear nor blind enthusiasm, but more thoughtful metabolic care for women in midlife?
Murray did not change her mind because the shortcuts suddenly became acceptable. She changed it because the evidence base expanded, the clinical stakes became clearer, and she saw what these medicines could mean when they are used as one tool in a larger, individualized plan.
She also tried a GLP-1 medication herself after a friend, Dr. Amiey Hornaman, challenged her to experience the treatment she had been criticizing. The starter dose did not register much. At the next dose, she was intensely nauseated. Even getting down a few ounces of chicken felt like a battle. That firsthand experience sharpened, rather than erased, her original concern: if a treatment makes protein, hydration, movement, and daily life feel impossible, the answer cannot be to simply push through toward a bigger number on the scale.
Medical note: This article is educational and does not replace individual medical care. Do not start, stop, obtain, or adjust a GLP-1 medication or hormone therapy from an article. A qualified prescriber should review your diagnosis, medical history, current medicines, pregnancy plans, risks, and follow-up plan.
Your metabolism did not fail a character test
For decades, women have heard a painfully familiar explanation for midlife body changes: eat less, move more, have more discipline. It is a patronizing story, and it misses the reality of the menopause transition.
Perimenopause can bring fluctuating hormones, disrupted sleep, changes in body composition, and a shift toward more abdominal fat. As estradiol declines, it stops doing its job as a master metabolic regulator: the hormone that sensitizes cells to insulin, protects blood vessels, supports mitochondrial function, and governs where the body stores fat. Insulin resistance rises even when diet has not changed, and fat redistributes to the deeper, more inflammatory visceral stores around the organs. The point is not that estrogen decline explains every pound. The point is that a changing waistline is not evidence of a moral failure.
That deeper visceral fat drives low-grade systemic inflammation, which is part of why cardiovascular risk, neuroinflammation, and bone loss accelerate after menopause. The American Heart Association notes that cardiovascular risk factors can increase across the menopause transition, beyond changes attributable to aging alone.[1] That is why a midlife conversation should look beyond the bathroom scale. Blood pressure, glucose, lipids, sleep, strength, symptoms, family history, and how a woman actually feels in her body belong in the picture.
Murray calls this a move away from chasing the woman you used to be and toward caring for the woman you are supposed to be right now. That is not settling. It is finally using the right map.
What changed my mind: these are not just “weight-loss drugs”
GLP-1 is short for glucagon-like peptide-1, a hormone involved in appetite and blood-sugar signaling. Medicines that act on the GLP-1 receptor can increase fullness and reduce food intake. Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors, which is why it is more accurately described as a dual GIP/GLP-1 medicine.[2]
Calling every GLP-1 medicine a cosmetic weight-loss drug leaves out important evidence. These are peptide hormones with receptors throughout the body, in the brain, heart, kidneys, liver, blood vessels, and immune cells, and part of their mechanism is anti-inflammatory. In major trials, markers of systemic inflammation such as high-sensitivity C-reactive protein drop significantly, and that drop appears independent of weight loss rather than merely a consequence of it. We now have data that HRT in perimenopause and menopause, along with GLP medications, improve GLP medication outcomes. It is not an either-or; it is a yes-and treatment. BHRT and GLP work synergistically better together.
In the randomized SELECT trial, 17,604 adults age 45 and older with established cardiovascular disease and overweight or obesity, but without diabetes, received semaglutide or placebo. Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of nearly 40 months.[3] That is meaningful, real-world-relevant evidence for that defined population. It is not proof that every healthy woman in perimenopause should take semaglutide to prevent a first heart attack.
The FLOW trial found that semaglutide reduced major kidney-disease events and cardiovascular death in people with type 2 diabetes and chronic kidney disease.[4] Again, this is not a generic promise of kidney protection for anyone who wants to feel better in midlife. It is a reminder that these medicines have a clinical role bigger than a before-and-after photo.
What Murray is advocating for is not a GLP-1 free-for-all. It is a more adult conversation: Which medicine, for what goal, for which woman, with what support?
Food noise is real. Food deprivation is not a treatment plan.
One reason women describe these medications as life-changing is “food noise.” For some people, relentless thoughts about food, urges, or cravings quiet down in a way they have not experienced before. That relief can be significant. It can also make it easier to see why willpower was never the whole story. Notably, the same reward-pathway effect shows up with alcohol and other cravings, which is part of why the research here is so interesting.
But appetite support is not the same thing as being unable to nourish yourself.
Murray’s own experience points to the line. If a person is so nauseated that protein is repulsive, fluids are difficult, and exercise becomes unrealistic, the care plan deserves a reassessment. Significant weight loss can include loss of lean mass as well as fat mass. That does not mean GLP-1s inevitably “destroy muscle.” It means muscle, nutrition, and bone health cannot be an afterthought.
The work around a medication still matters:
- Make room for enough food and fluid. Protein is the anchor. Murray targets roughly 1 to 1.2 grams per pound of goal lean body mass, which puts most midlife women at about 100 to 120 grams a day as a floor, adjusted for body size, kidney health, and activity. If the medicine leaves you unable to hit that, the dose, not your effort, is the problem to fix.
- Keep strength in the plan. Resistance activity is a powerful signal to muscle and bone. The CDC recommends muscle-strengthening work for major muscle groups on at least two days a week, adapted to a person’s ability and health status.[5] Murray favors progressive resistance training three to four times a week, with the last couple of reps genuinely hard, because that is where muscle and bone growth are signaled.
- Watch function, not only weight. Strength, stamina, sleep, side effects, and the ability to eat a varied diet tell a more useful story than the scale alone.
- Bring symptoms back to the prescriber early. Persistent vomiting, inability to maintain fluids, or severe abdominal pain needs prompt medical attention, not a pep talk about tolerating the dose.
This is where rushed prescribing fails women. A medication that changes appetite needs a plan that protects what appetite was helping sustain.
Low-dose and “microdosing”: where the real clinical interest is
Murray’s episode raises the question many midlife women are already asking: could a much lower dose quiet food noise without the nausea that makes it impossible to eat, train, and live?
This is where a lot of forward-looking practitioners have moved, including the medical teams at Dr. Murray’s clinic, Living Well Dallas Functional Medicine Center. Rather than pushing a patient up a standard titration schedule to a maximal dose, many are using a sub-therapeutic, minimum effective dose, sometimes called microdosing. The goal is not maximal appetite suppression. It is to turn off the intrusive food noise while still allowing a woman to eat enough protein and keep lifting and impact anti-inflammatory pathways that seem to be modulated by GLP or GIP signals. In practice, that can mean better appetite control, steadier post-meal blood sugar, improved insulin sensitivity, and an anti-inflammatory benefit, without the nausea, vomiting, and fatigue that come at higher doses.
Two honest caveats belong here, and Murray names them. First, this is not how these drugs were FDA-approved or studied, so the microdosing benefit is clinical and anecdotal, reported by the functional-medicine practitioners using it, not yet proven in large randomized trials. Second, dosing is a clinical decision, not a DIY one. Do not reduce, stretch, escalate, or otherwise adjust your own dose or injection schedule. Source still matters. Don’t buy black-market GLP drugs online. Work with a knowledgeable provider. If the medication is too much, talk to your prescriber about lowering the dose and reassessing your inflammatory markers, glucose, and appetite before escalating.
Hormones are not optional background: they may be the main event
This is where the midlife lens matters most. A woman may have metabolic concerns and very real menopause symptoms at once, hot flashes, night sweats, disrupted sleep, mood changes, bone-health risk. She deserves a provider who treats the whole picture, not each symptom in a silo.
Dr. Murray is direct about where hormones sit in that picture. Replacing the estrogen and progesterone the ovaries stop making is, in her words, probably the most powerful longevity intervention available in midlife, not a nice-to-have alongside a GLP-1. Estrogen helps preserve muscle protein synthesis, supports bone mineral density, keeps baseline metabolic rate intact, improves insulin sensitivity, and reduces the inflammatory load of visceral fat. A GLP-1 addresses insulin resistance, visceral fat, and food noise. Used together, they are synergistic: as she puts it, the GLP-1 does more when the hormones are on board. Recent observational data, including a 2024 Mayo Clinic analysis of postmenopausal women on semaglutide, found greater fat loss among those also using hormone therapy, an association that still needs randomized confirmation but points the same direction as the biology.[8]
A better appointment starts with better questions
Murray’s advocacy is rooted in a simple belief: you should have a clinician who works with you as an intelligent partner. If you are symptomatic in perimenopause, that alone can warrant treatment, and you do not have to have labs first. But she likes knowing where she is starting, because you cannot map a route without knowing the first turn. When a woman is re-engineering her metabolism, the data she finds most useful includes:
- A DEXA scan for body composition and bone mineral density, so you can see visceral fat, lean mass, and where bone stands.
- A full metabolic panel: fasting glucose, fasting insulin, hemoglobin A1c, lipids, and lipoproteins including ApoB and ApoA1, to read true cardiovascular and insulin-resistance risk that fasting glucose alone cannot show.
- Inflammatory markers such as hs-CRP.
- Sex Hormones, even in perimenopause: estradiol, progesterone, total and free testosterone.
- A full thyroid panel: TSH, T4, T3, free T3, free T4, thyroid antibodies, and reverse T3 when available.
- DHEA-sulfate and cortisol for a fuller picture of the metabolic hormones riding along with the sex hormones and thyroid.
From there, anchor any GLP-1 in a muscle-centric foundation: protein minimums and progressive resistance training come first, not as an afterthought. Then bring these questions to the visit:
- What are we treating? Is my goal diabetes management, an approved weight-related indication, cardiovascular risk in an eligible population, sleep apnea, menopause symptoms, or something else?
- Am I eligible, and is this product right for me? Ask about your health history, current medications, history of pancreatitis or serious gastrointestinal problems, kidney concerns, and diabetes treatments that may raise the risk of low blood sugar.
- Are there reasons this medicine is not appropriate for me? GLP-1 product labels carry serious warnings and list contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnancy planning also matters, even if periods have become irregular.[2]
- How will we protect nutrition and strength? Ask what follow-up will look like if food intake, hydration, strength, or daily function begin to slip.
- Do I separately need a menopause conversation? Hot flashes and other menopause symptoms are not automatically solved by metabolic medication. If MHT is under consideration, it deserves its own shared decision.
And before starting any chronic medication, ask the question people often skip: what happens if I need to stop? In the STEP 1 extension, participants who stopped semaglutide and the lifestyle program regained, on average, about two-thirds of their prior weight loss over the following year.[9] That is not a personal failure. It is a reminder that obesity and metabolic health often require longer-term planning, not a temporary crash course.
GLP-1s and menopause: questions women are actually asking
Can I use a GLP-1 during perimenopause?
Possibly, if you meet the eligibility criteria for a specific FDA-approved indication and have no contraindications. Perimenopause itself is not an indication. Your symptoms, medical history, pregnancy potential, medications, and ability to receive follow-up all matter.[2]
Will a GLP-1 treat my hot flashes or replace hormone therapy?
No. GLP-1 medicines are not established treatments for hot flashes or night sweats. MHT is often the most effective option for bothersome menopause symptoms, and Murray considers hormones foundational in midlife care, but hormone therapy is its own clinical decision.[7]
Is a low-dose or microdose GLP-1 safer for muscle and metabolism?
It can be a smart way to get the food-noise and anti-inflammatory benefit without the nausea that wrecks protein intake, which is why many functional-medicine clinicians use low, targeted doses. It is not FDA-approved or trial-proven as a protocol, so it belongs in the hands of a prescriber who knows the product and your history. Do not self-adjust.[6]
Can I take MHT and a GLP-1 together?
Yes, when each has an independent clinical reason, and Murray views the combination as synergistic. Early observational research suggests greater weight loss when hormone therapy is on board, consistent with estrogen’s role in muscle, bone, and insulin sensitivity, though randomized trials are still needed.[8]
Changing your mind is not weakness. It is good medicine.
Murray has also told her own midlife story: a roughly 30-pound gain as she entered perimenopause, followed by years of digging through the research, reassessing, and understanding how hormonal change affected her metabolism, which is how she reversed gears and has kept the weight off for over eight years. That personal experience is not a prescription for another woman. It is part of why this conversation carries so much urgency.
Women have spent too long being told their symptoms are normal, their changing bodies are a discipline problem, or their only option is a quick pharmaceutical answer handed over with no instruction manual. We can expect more. True healthspan uses every validated, evidence-informed tool available, applied intelligently and safely with a care team that listens and captures data, rather than waiting decades for a trial on every single question.
The better question is not, “Should every woman be on a GLP-1?” The better question is: What does my body need now, and does this tool belong in a plan that helps me feel stronger, healthier, and more like myself?
At Menrva, we believe midlife care begins with listening closely, taking symptoms seriously, and using data and treatment options without reducing a woman to a number on a scale. If this conversation gives you language for your next appointment, share it with a friend, a sister, or someone you love who has been trying to navigate these changes alone. Keep asking better questions, demand better data, and own your midlife mastery.
